Arca
Skip to content

Metastatic cancers

Drug research and approvals for metastatic cancers: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 3,265 studies of metastatic cancers are recruiting on ClinicalTrials.gov, and Health Canada has authorized 7 drug trials for it since 2013.

  • Recruiting worldwide: 3,265
  • Trials authorized in Canada: 7
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 3,265 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

Newest first; search them all in Canada trials
Sep 25, 2025A phase 1/2, multicenter, open label, dose escalation & dose expansion study of jk06, a 5t4 antibody drug conjugate, in patients with unresectable locally…JK06SALUBRIS BIOTHERAPEUTICS, INC.Ongoing
Aug 4, 2023A phase 1/2, first-in-human, open-label, dose-escalation study of tak-280 in patients with unresectable locally advanced or metastatic cancerTAK-280Takeda Pharmaceuticals USAClosed
Oct 20, 2022A randomized, open-label, multicenter phase 3 trial of domvanalimab, zimberelimab, and chemotherapy versus nivolumab and chemotherapy in participants with…ZIMBERELIMAB (AB122) / DOMVANALIMAB (AB154) / OXALIPLATIN / LEUCOVORIN /…ARCUS BIOSCIENCES, INC.Closed
Feb 24, 2021In vivo lung perfusion (ivlp) as an adjuvant treatment for patients with resectable or unresectable pulmonary metastases of colorectal carcinomasOXALIPLATINUNIVERSITY HEALTH NETWORKOngoing
Jan 14, 2020A phase 1/2a two-part, open-label, multicenter study to evaluate the safety and pharmacokinetics of oc-001 as monotherapy and in combination with an anti-pd-l1…OC-001OCELLARIS PHARMA, INC.Ongoing
Mar 13, 2019Phase 1 study of zw49 in patients with locally advanced (unresectable) or metastatic her2-expressing cancersZW49 INJECTIONZYMEWORKS BC INC.Ongoing
Feb 16, 2018Phase 1 trial of zw25 in patients with locally advanced (unresectable) and/or metastatic her2-expressing cancersZW25Jazz PharmaceuticalsOngoing

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.